产品说明书

Gemfibrozil

Print
Chemical Structure| 25812-30-0 同义名 : CI-719
CAS号 : 25812-30-0
货号 : A640007
分子式 : C15H22O3
纯度 : 98%
分子量 : 250.33
MDL号 : MFCD00079335
存储条件：

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(419.45 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 PPAR (peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of PPARα, PPARγ, and PPARβ/δ[3]. Gemfibrozil is a PPARα and PPARγ agonist (EC50s = 193.3 and 147.8 µM, respectively)[4]. In vivo, gemfibrozil (50 mg/kg, p.o.) reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia[5]. Gemfibrozil (100 mg/kg per day) reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.99mL

0.80mL

0.40mL

19.97mL

3.99mL

2.00mL

39.95mL

7.99mL

3.99mL
参考文献

[1]Pahan K, Jana M, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002;277(48):45984-91

[2]Prueksaritanont T, Zhao JJ, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002 Jun;301(3):1042-51.

[3]Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011 Oct;2(4):236-40.

[4]Kim NJ, Lee KO, Koo BW, et al. Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists. Bioorg Med Chem Lett. 2007;17(13):3595-3598.

[5]Solanki YB, Jain SM. Antihyperlipidemic activity of Clitoria ternatea and Vigna mungo in rats. Pharm Biol. 2010;48(8):915-923.

[6]Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 2006;49(4):766-774.